Leukaemia (chronic lymphocytic, relapsed) - rituximab: review decision - March 2014 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix B: GE decision paper - March 2014
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: Review Proposal - January 2014 information
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: Appendix A - provisional matrix of stakeholders
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: Appendix B - proposal paper presented to the Institute's Guidance Executive
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - October 2012 information
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - December 2010 information
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal information
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: notice of appeal information
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal announcement information
-
Appeal: UK Chronic Lymphocytic Leukaemia (CLL) Forum
-
Appeal received
-
-
Initial scrutiny letter
-
-
Response to initial scrutiny letter
-
-
Final scrutiny letter
-
-
Appraisal committee chair's response
-
-
Response to appraisal committee
-
-
Appeal: Joint: Royal College of Pathologists and British Society for Haematology
-
Appeal received
-
-
Initial scrutiny letter
-
-
Response to initial scrutiny letter
-
-
Final scrutiny letter
-
-
Appraisal committee response
-
-
Response to appraisal comittee
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal decision
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appeal decision (PDF 35 KB)
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final appraisal determination
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final appraisal determination information
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final appraisal determination
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final appraisal determination (PDF 133 KB)
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: ERG response to error identified by manufacturer at consultation
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - Royal College of Pathologists
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - RCN
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - Cancer Research UK
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: consultee and commentator comments on the ACD - Roche
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD - Williams
-
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: expert comments on the ACD - Barnard
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appraisal consultation document
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appraisal consultation document
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: appraisal consultation document information
-
Evaluation report
-
Pre-meeting briefing
-
-
Evidence Review Group report
-
-
Non-manufacturer submissions
-
UK CLL Forum
-
-
Royal College of Physicians
-
-
Royal College of Pathologists
-
-
Royal College of Nursing
-
-
NICE Submission - Rituximab for the treatment of relapsed/refractory Chronic Lymphocytic Leukaemia
-
-
Clarification stage
-
Manufacturer response to clarification - Roche response
-
Manufacturer response to clarification - Roche response (PDF 1021 KB)
-
Manufacturer response to clarification - Response to request for clarification regarding PFS fit
-
-
NICE clarification - Parameters for curve fits
-
-
NICE clarification - letter
-
-
Expert written personal statements
-
Williams Durkin
-
-
Barnard
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope (updated)
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope (updated)
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope (PDF 25 KB)
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: final scope (PDF 25 KB)
Leukaemia (chronic lymphocytic, relapsed) - rituximab: response to consultee and commentator comments on the draft scope
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: response to consultee and commentator comments on the draft scope
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: response to consultee and commentator comments on the provisional matrix
-
Leukaemia (chronic lymphocytic, relapsed) - rituximab: response to consultee and commentator comments on the provisional matrix
-